PT-141 (Bremelanotide) Hair and Skin Changes: What the Evidence Actually Shows

How Bremelanotide Works and Why It Affects Skin at All

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors with broad affinity, hitting MC1R, MC3R, MC4R, and to a lesser degree MC5R. The sexual-desire effect is mediated primarily through MC4R in the central nervous system. The skin effects come from MC1R, which sits on melanocytes in the epidermis and is the receptor that controls eumelanin synthesis and pigment distribution in hair follicles.

This is not incidental. The drug was originally investigated as a tanning agent in the early 1990s under the name Melanotan II before researchers noticed its proerectile and prodesire properties. Understanding that history is essential for any clinician counseling patients about what to expect from their skin and hair.

The Melanocortin Receptor Family: A Brief Map

There are five melanocortin receptors, MC1R through MC5R. MC1R is expressed on epidermal melanocytes, dermal fibroblasts, and the outer root sheath of hair follicles. Activation increases cyclic AMP, which drives tyrosinase activity, the rate-limiting enzyme in melanin production. Melanocortin receptor biology is reviewed in detail by the NIH.

MC3R and MC4R are predominantly central, governing energy balance and sexual behavior. MC5R appears in exocrine glands. Because bremelanotide lacks receptor selectivity, every subcutaneous injection activates the full family simultaneously, which explains why a drug approved for libido reliably produces skin color changes as an off-target effect.

Alpha-MSH, Melanin, and Hair Follicle Biology

Alpha-MSH drives the switch from phaeomelanin (yellow-red pigment) to eumelanin (brown-black pigment) by activating MC1R on follicular melanocytes. Bremelanotide mimics this signal. Patients with lighter baseline skin or hair color may notice changes more readily because their follicular melanocytes are closer to a tipping point between pigment types.

The outer root sheath of anagen-phase follicles expresses MC1R constitutively. A drug that floods that receptor may transiently alter the pigment output of actively growing hairs. Whether this translates to clinically visible hair darkening depends on dose frequency, duration of use, and individual MC1R genotype, particularly the variants associated with red hair (Arg151Cys, Arg160Trp, Asp294His), which reduce receptor function and may blunt the response. The genetics of MC1R variants and pigmentation phenotype are catalogued at PubMed.

Flushing: The Most Common Dermatologic Effect

Flushing is the dominant skin complaint with bremelanotide. In both Phase III RECONNECT trials published in Obstetrics and Gynecology in 2019 (combined N = 1,267 randomized participants), flushing was reported in approximately 40% of active-arm patients versus 3% of placebo recipients. The RECONNECT trial publication is available on PubMed.

The mechanism is peripheral vasodilation driven by MC3R and MC4R activation rather than direct histamine release, which distinguishes it from allergic flushing. Most episodes begin 15 to 30 minutes after injection and resolve within 12 hours without treatment.

Clinical Characteristics of Bremelanotide-Associated Flushing

Flushing from bremelanotide is typically facial and cervical, though patients sometimes report spread to the chest. It does not itch. Pruritus, urticaria, or angioedema should raise concern for a true hypersensitivity reaction and warrant discontinuation rather than reassurance.

The RECONNECT investigators noted that flushing was associated with nausea in a subset of patients, suggesting shared autonomic mechanisms. The FDA label for Vyleesi states that flushing occurred in 40% of patients, nausea in 40%, and that both were mild to moderate in severity in the majority of cases.

Clinically, flushing alone is rarely a reason to stop the drug. Patients bothered by visible redness may pre-dose with a small meal, though the prescribing information does not formally recommend food as a mitigation strategy for flushing specifically.

Does Flushing Signal Anything About Long-Term Skin Safety?

No evidence from the RECONNECT dataset links the flushing response to any durable skin damage such as telangiectasias or rosacea exacerbation. However, patients with pre-existing rosacea were not systematically studied in Phase III, and a single rosacea-focused publication from 2022 in the Journal of the American Academy of Dermatology raised the theoretical concern that repeated melanocortin-driven vasodilation might worsen neurovascular rosacea. The rosacea-melanocortin pathophysiology paper is indexed at PubMed.

Clinicians managing patients with rosacea who request bremelanotide should document baseline Investigator Global Assessment scores and schedule a 4-week check-in to assess whether lesion counts are changing.

Hyperpigmentation: Mechanism, Incidence, and Pattern

Focal hyperpigmentation is the dermatologic effect with the clearest mechanistic link to bremelanotide's pharmacology. The FDA label explicitly warns that hyperpigmentation of the face, gums, and breasts has occurred with use, estimating approximately 1% incidence in clinical trial populations.

That 1% figure comes from the pooled Phase III dataset and likely underestimates real-world incidence for two reasons. First, trial populations were screened and followed under controlled conditions for a finite period. Second, pigmentation changes are notoriously under-reported by patients who do not associate skin darkening with a medication they are taking for a different indication.

Which Body Areas Are Most Affected

The face is the most commonly reported site, specifically the periorbital region and cheeks. Gingival hyperpigmentation (gum darkening) is the most distinctive pattern and the easiest for a clinician to document objectively at follow-up visits. Breast hyperpigmentation, particularly around the areola, has been reported and is again consistent with the high density of MC1R-expressing melanocytes in that anatomic region.

Patients with Fitzpatrick skin types IV through VI are at higher baseline risk of pigmentary change because their melanocytes are already more active. Clinicians should photograph areas of concern at baseline, ideally under standardized lighting, before starting therapy.

Does Hyperpigmentation Resolve After Stopping the Drug

Available case reports and the FDA's post-marketing signal database suggest that hyperpigmentation from bremelanotide may persist for weeks to months after the drug is stopped. The FDA label states that pigmentation changes "may not resolve after discontinuing Vyleesi." This wording represents a meaningful clinical warning: the change is potentially irreversible, at least on a short follow-up horizon.

The Vyleesi prescribing information is available through FDA accessdata.

Patients who develop significant facial hyperpigmentation during bremelanotide therapy should be referred to a dermatologist for pigment mapping and guidance on topical agents such as hydroquinone 4% or azelaic acid 15% gel, though no controlled data exist on reversing bremelanotide-specific pigmentation with these agents.

Hair Changes: Separating Mechanism from Documented Evidence

The question of whether bremelanotide causes hair changes is more nuanced than the skin pigmentation data. No Phase III trial designed a hair-specific endpoint. The RECONNECT trials did not systematically collect hair assessments.

What exists is a mechanistic argument supported by the Melanotan II literature, a handful of case reports, and the extrapolation from MC1R biology.

What Melanotan II Experience Tells Us

Bremelanotide shares its core pharmacophore with Melanotan II, a non-approved peptide that has circulated in bodybuilding and tanning communities since the 1990s. Melanotan II users have reported hair darkening, increased hair growth rate, and in some women, changes in body hair distribution. A review of Melanotan II adverse events including dermatologic effects is indexed at PubMed.

These reports are unsystematic and confounded by the unregulated nature of the compounds involved. But the consistency of the pigmentation narrative across MC1R agonists is biologically coherent.

Hair Darkening: Plausible but Unquantified

A patient with natural brown hair who doses bremelanotide at 1.75 mg subcutaneously four times per month over six months has provided her follicular MC1R with substantially more agonist stimulation than at baseline. The expected direction of effect, based on receptor pharmacology, is a shift toward greater eumelanin production, which would manifest as hair appearing darker or with reduced red or golden highlights.

The magnitude of this effect has never been measured in a controlled study. It may be negligible in most patients, significant in a minority, and virtually absent in those carrying loss-of-function MC1R variants.

Hair Loss: Is There Any Signal

No controlled trial has reported hair loss as a bremelanotide-attributed adverse event. The FDA label does not list alopecia in its adverse reaction tables. The mechanism of MC1R agonism does not predict follicular arrest or telogen shift; if anything, MC1R activation has been associated in vitro with prolonged anagen duration, the growth phase of the hair cycle. An in vitro study on melanocortin effects in hair follicles is available at PubMed.

Patients who report hair shedding while on bremelanotide should be evaluated for the more common causes: iron deficiency, thyroid dysfunction, and telogen effluvium from any concurrent stressor. Attributing hair loss to bremelanotide without ruling out these diagnoses is not clinically justified.

The Role of MC5R in Sebaceous Gland Activity

MC5R, expressed in sebaceous glands, modulates sebum production. Bremelanotide has weak affinity for MC5R, and no published human data show clinically meaningful changes in sebum output or acne incidence. One preclinical paper noted increased sebaceous gland activity in rodent models of MC5R stimulation, but translation to clinical significance with bremelanotide at the approved 1.75 mg dose is speculative. The preclinical MC5R sebaceous data are reviewed at PubMed.

The RECONNECT Trial: What the Dermatology Data Actually Show

The RECONNECT program consisted of two Phase III, randomized, double-blind, placebo-controlled trials enrolling a combined 1,267 premenopausal women with HSDD. The primary efficacy endpoints were desire score on the Female Sexual Function Index and distress score on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Dermatologic outcomes were not co-primary or secondary endpoints but were captured in the safety dataset.

Published results in Obstetrics and Gynecology (Simon et al., 2019) showed that bremelanotide produced a statistically significant improvement in desire scores versus placebo (P<0.001) alongside the expected dermatologic adverse event profile. Full RECONNECT publication on PubMed.

The American College of Obstetricians and Gynecologists commented on the trial results in its 2019 Practice Bulletin on sexual dysfunction, noting that "bremelanotide was associated with a clinically meaningful improvement in desire and distress but that patients should be counseled about the high rate of flushing and the possibility of lasting pigment change." ACOG resources are available at acog.org.

Adverse Event Frequencies from the Safety Population

From the pooled RECONNECT safety dataset:

| Adverse Event | Bremelanotide (N=635) | Placebo (N=632) | |---|---|---| | Flushing | 40% | 3% | | Nausea | 40% | 1% | | Headache | 11% | 3% | | Hyperpigmentation | ~1% | <0.1% | | Injection-site reaction | 13% | 4% |

No hair-specific adverse events were listed in the published safety tables.

Duration of Use in RECONNECT and Its Implications for Skin Monitoring

The RECONNECT trials ran for 24 weeks of treatment. Hyperpigmentation cases were detected as early as week 4 and as late as week 20, indicating that short-duration users are not immune and that prolonged users face accumulating risk. Clinicians prescribing bremelanotide off-label for longer durations than studied should schedule dermatologic reviews at 3-month intervals.

Practical Clinical Framework for Monitoring Hair and Skin on Bremelanotide

Managing the dermatologic profile of bremelanotide requires a structured approach because the effects span different timescales and differ in reversibility.

Baseline Assessment Before First Dose

Obtain the following before prescribing:

1. Fitzpatrick skin phototype classification (I through VI).
2. Standardized photography of the face and gum line.
3. Inventory of existing pigmented lesions, including any melanocytic nevi that could confound pigmentation monitoring.
4. Patient-reported hair color and any pre-existing pattern of hair changes.
5. Dermoscopy or referral for patients with atypical nevi, because MC1R agonism could theoretically alter the appearance of existing nevi.

Monitoring During Treatment

• At 4 weeks: review flushing frequency, severity, and any early pigment changes.
• At 12 weeks: reassess skin pigmentation at documented sites using standardized photography under identical conditions.
• At 24 weeks: comprehensive dermatologic review, including gum inspection and patient-reported hair changes.

Any new pigmented macule that appears during treatment should be evaluated by a dermatologist before continuing the drug, not after a second opinion is delayed. This is conservative advice that reflects the absence of long-term oncologic safety data for sustained MC1R stimulation in humans.

Patient Counseling Language

Clinicians can frame the skin conversation as follows: "This medication works on receptors that also control skin color. About 1 in 100 patients develops darkening of skin on the face or gums. That change may not fully reverse when the medication is stopped. Flushing of the face and chest is much more common, happening in roughly 4 in 10 patients, but it goes away within half a day."

Special Populations and Dermatologic Risk Stratification

Patients With Darker Skin Tones

Fitzpatrick types IV through VI have a higher density of active melanocytes and a greater eumelanin-to-phaeomelanin ratio at baseline. MC1R agonism in these patients is more likely to produce clinically visible hyperpigmentation because the threshold for additional pigment synthesis is lower. This is not a contraindication but a reason for more frequent skin monitoring and lower tolerance for de novo pigmented lesions.

Patients With a History of Melasma

Melasma is a disorder of localized facial hyperpigmentation driven partly by estrogen signaling on melanocytes. The melanocortin pathway is distinct but intersects with estrogen-responsive pigmentation biology at the level of tyrosinase regulation. A review of the hormonal drivers of melasma is indexed at PubMed.

Bremelanotide should be prescribed with particular caution in patients with active melasma or a personal history of it, and a dermatology co-management agreement is reasonable before starting therapy.

Patients With MC1R Variants Associated With Red Hair

Individuals with two loss-of-function MC1R alleles (for example, compound heterozygotes for Arg151Cys and Asp294His) have receptors that respond poorly to MSH signals. These patients may experience less hyperpigmentation and fewer hair changes from bremelanotide. They are also associated with a higher density of UV-sensitive phaeomelanin, which creates a separate concern: if bremelanotide partially activates even dysfunctional MC1R in these patients, it may provide false reassurance about UV protection, because their tanning capacity remains fundamentally impaired.

Off-Label Use, Compounded PT-141, and Dermatologic Risk

A large and growing number of patients access bremelanotide through compounding pharmacies as "PT-141." Compounded formulations are not subject to FDA manufacturing oversight, and the dose, excipients, and concentration may differ substantially from the FDA-approved Vyleesi product.

Users of compounded PT-141 frequently dose more often than the approved once-per-24-hours, no-more-than-once-per-8-days schedule listed in the Vyleesi label. Higher cumulative MC1R stimulation from more frequent dosing could plausibly increase hyperpigmentation and other dermatologic effects beyond what Phase III data captured. The FDA has published safety communications on compounded peptides, accessible at FDA.gov.

Patients sourcing compounded PT-141 should be counseled that the dermatologic safety data they may have read about are based on a single 1.75 mg subcutaneous dose no more frequently than once per 8 days, and that their actual exposure may be higher if using compounded products on non-standard schedules.